TSND-201 Demonstrated Rapid, Robust, and Durable Therapeutic Efficacy in a Randomized, Placebo-Controlled Trial (IMPACT-1) for the Treatment of Post-Traumatic Stress Disorder

Summary of Presentation: Treatment with TSND-201 resulted in rapid and robust improvements in PTSD symptoms Placebo-adjusted CAPS-5 improvement of -9.64 points on Day 64 (p=0.012) Durable efficacy following an acute episodic dosing regimen (once per week for 4-weeks) TSND-201 was generally safe and well tolerated, with a safety profile consistent with its non-hallucinogenic pharmacology View Poster

The release as fetched from its publisher. transcendtherapeutics.com ↗